REC-994 is a potent, selective superoxide dismutase mimetic. Its mechanism of action has preclinical proof of concept to impact lesion development in a mouse model of CCM. It has been granted orphan drug designation by the US FDA and the EMA.
CCM is a genetic disease resulting in collections of small blood vessels in the brain that are enlarged and irregular in structure and which lead to altered blood flow. While these malformations can occur anywhere in the body, CCMs occurring in the brain cause severe symptoms, including seizures, vision and hearing loss, paralysis, other focal neurologic deficits and/or hemorrhagic stroke.
Recursion Pharmaceuticals combines artificial intelligence, experimental biology, and automation to identify and de-risk potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease.
The company applies causative perturbations to human cells to generate disease models and associated biological image data. Its database of biological images is then probed using advanced machine learning approaches, revealing drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial